U.S. markets open in 3 hours 52 minutes
  • S&P Futures

    4,398.25
    +4.50 (+0.10%)
     
  • Dow Futures

    34,939.00
    +105.00 (+0.30%)
     
  • Nasdaq Futures

    14,995.50
    -16.00 (-0.11%)
     
  • Russell 2000 Futures

    2,236.40
    +15.70 (+0.71%)
     
  • Crude Oil

    72.96
    +0.57 (+0.79%)
     
  • Gold

    1,820.70
    +21.00 (+1.17%)
     
  • Silver

    25.57
    +0.69 (+2.77%)
     
  • EUR/USD

    1.1878
    +0.0031 (+0.26%)
     
  • 10-Yr Bond

    1.2610
    0.0000 (0.00%)
     
  • Vix

    17.79
    -1.57 (-8.11%)
     
  • GBP/USD

    1.3952
    +0.0043 (+0.31%)
     
  • USD/JPY

    109.8300
    -0.0800 (-0.07%)
     
  • BTC-USD

    40,172.65
    +385.81 (+0.97%)
     
  • CMC Crypto 200

    940.83
    +10.90 (+1.17%)
     
  • FTSE 100

    7,065.88
    +49.25 (+0.70%)
     
  • Nikkei 225

    27,782.42
    +200.76 (+0.73%)
     

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

·4 min read

Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?

So should Anixa Biosciences (NASDAQ:ANIX) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

Check out our latest analysis for Anixa Biosciences

Does Anixa Biosciences Have A Long Cash Runway?

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at April 2021, Anixa Biosciences had cash of US$38m and such minimal debt that we can ignore it for the purposes of this analysis. Looking at the last year, the company burnt through US$5.1m. Therefore, from April 2021 it had 7.4 years of cash runway. Even though this is but one measure of the company's cash burn, the thought of such a long cash runway warms our bellies in a comforting way. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Anixa Biosciences' Cash Burn Changing Over Time?

In our view, Anixa Biosciences doesn't yet produce significant amounts of operating revenue, since it reported just US$513k in the last twelve months. As a result, we think it's a bit early to focus on the revenue growth, so we'll limit ourselves to looking at how the cash burn is changing over time. With cash burn dropping by 6.3% it seems management feel the company is spending enough to advance its business plans at an appropriate pace. While the past is always worth studying, it is the future that matters most of all. So you might want to take a peek at how much the company is expected to grow in the next few years.

How Easily Can Anixa Biosciences Raise Cash?

Even though it has reduced its cash burn recently, shareholders should still consider how easy it would be for Anixa Biosciences to raise more cash in the future. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

Since it has a market capitalisation of US$128m, Anixa Biosciences' US$5.1m in cash burn equates to about 4.0% of its market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.

So, Should We Worry About Anixa Biosciences' Cash Burn?

It may already be apparent to you that we're relatively comfortable with the way Anixa Biosciences is burning through its cash. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. Its weak point is its cash burn reduction, but even that wasn't too bad! After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. On another note, Anixa Biosciences has 5 warning signs (and 2 which can't be ignored) we think you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.